Latest Phosphoinositide 3-kinase Stories
Caris Molecular Intelligence Tumor Profiling Data Presented at ASCO Highlights Drug Efflux Pump Expression and PIK3CA Pathway Aberrations from 50,000 Tumors and 20,000 Tumors Respectively
DUBLIN, May 13, 2015 /PRNewswire/ -- Research and Markets ( http://www.researchandmarkets.com/research/42hpkb/nontyrosine) has announced the addition of the "Non-Tyrosine
DUBLIN, April 14, 2015 /PRNewswire/ -- Research and Markets ( http://www.researchandmarkets.com/research/vktrnv/tyrosine_kinase) has announced the addition of the "Tyrosine
LONDON, Oct. 14, 2014 /PRNewswire/ -- REPORT HIGHLIGHTSThe global market for signal transduction therapies/inhibitors (JAK and PI3K) reached $173.5 million in 2012.
- Infinity to Receive $275 Million Upfront Payment and $530 Million in Potential Milestones - CAMBRIDGE, Mass. and NORTH CHICAGO, Ill., Sept.
According to a new report from BCC Research, the global market for signal transduction therapies/inhibitors (JAK and PI3K) is expected to grow to $2.2 billion by 2018, with a five-year compound
QUÉBEC CITY, April 9, 2014 /PRNewswire/ - Aeterna Zentaris Inc.
QUÉBEC CITY, April 1, 2014 /PRNewswire/ - Aeterna Zentaris Inc.
In the study by Toulany et al., it was demonstrated for the first time that long term treatment with inhibitors of PI3K (as it is performed clinically) results in a reactivation of the major survival component Akt through a so far unknown regulatory loop via ERK1/2.
Researchers from UCLA's Jonsson Comprehensive Cancer Center led an international team of scientists in conducting two studies that provide critical insights into two important ways that tumors resist BRAF inhibitors.
- To befool; deceive; balk; jilt.
- An illusion; a trick; a cheat.